Author Archives:

FDA approves COVID-19 treatment after successful use of STEM CELLS from RESTEM

CORONA, Calif., and MIAMI and SIOUX FALLS, S.D., May 14, 2020 — RESTEM, a leading cell-based therapeutics company, announced today it has received approval from the U.S. Food and Drug Administration (FDA) for a 60-patient Phase I/IIa study using umbilical cord mesenchymal stem cells to treat patients with severe cases of COVID-19. The study will be the first of its kind in the U.S.  “We are […]